Newsroom

法國里昂--(BUSINESS WIRE)--(美國商業資訊)-- Brenus Pharma今日宣布其董事會的重要人事任命。該公司歡迎Eric DESSERTENNE擔任總裁兼董事會主席，接替將繼續留任為活躍董事會成員的共同創辦人Jacques GARDETTE。Eric在醫療保健創新與價值創造方面擁有豐富經驗，曾主導BIOCORP的發展歷程及其後續由Novo Nordisk收購之事宜。Brenus亦任命Camilla SYLVEST為第二位獨立董事，並且此前已延攬資深且深耕美國生技領域的高階主管及企業家Diala EZZEDDINE。 Camilla SYLVEST是一位經驗豐富的製藥高階主管與全球商業領袖，曾在Novo Nordisk A/S服務近三十年，其最後職務為全球商業策略、企業溝通與永續發展執行副總裁。她目前擔任Argenx SE、Getinge AB及Zealand Pharma A/S之董事會成員，亦曾為Danish Crown A/S董事會成員，並擔任過世界糖尿病基金會副主席。 Brenus Pharma執行長Paul BRAVETTI表示：「Eric出色的實績，加...

LYON, Francia--(BUSINESS WIRE)--Brenus Pharma acaba de anunciar varios nombramientos clave para su consejo de administración. La empresa da la bienvenida a Eric DESSERTENNE como presidente. Asimismo, ocupará la presidencia del consejo de administración en sustitución del cofundador Jacques GARDETTE, quien seguirá siendo miembro activo del consejo. Eric aporta una amplia experiencia en innovación sanitaria y creación de valor después de haber dirigido con éxito BIOCORP a lo largo de su desarroll...

LIONE, Francia--(BUSINESS WIRE)--Brenus Pharma oggi ha annunciato importanti novità nel proprio consiglio di amministrazione. L'azienda dà il benvenuto a Eric DESSERTENNE, che assume il doppio incarico di presidente dell'azienda e del consiglio di amministrazione al posto del co-fondatore Jacques GARDETTE, che mantiene una partecipazione attiva nel CdA. Eric apporta una vasta esperienza nell'innovazione e nella creazione di valore nel comparto sanitario, maturata in particolare in BIOCORP nel c...

LYON, Frankrijk--(BUSINESS WIRE)--Brenus Pharma maakte vandaag belangrijke benoemingen bij zijn raad van bestuur bekend. Het bedrijf verwelkomt Eric DESSERTENNE als hoofd en voorzitter van de raad, ter opvolging van medeoprichter Jacques GARDETTE, die actief lid van de raad blijft. Eric heeft ruime ervaring op het vlak van innovatie in de gezondheidszorg en het creëren van waarde, met name aan het hoofd van BIOCORP tijdens zijn ontwikkeling en overname door Novo Nordisk. Brenus benoemt ook Cami...

里昂，法国--(BUSINESS WIRE)--(美国商业资讯)-- Brenus Pharma今日宣布其董事会的重要任命。公司迎来Eric DESSERTENNE担任总裁兼董事会主席，接替联合创始人Jacques GARDETTE，后者将继续担任董事会成员。Eric在医疗创新和价值创造方面拥有丰富的经验，特别是在领导BIOCORP的发展以及被Novo Nordisk收购的过程中贡献卓越。此外，Brenus还任命Camilla SYLVEST担任第二位独立董事，而在此前，经验丰富的美国生物技术高管和企业家Diala EZZEDDINE刚刚加入Brenus。 Camilla SYLVEST是一位经验丰富的制药行业高管和全球商业领袖，曾在Novo Nordisk A/S工作近三十年，最近担任该公司全球商业战略、企业传播与可持续发展执行副总裁。她目前担任Argenx SE、Getinge AB和Zealand Pharma A/S的董事会成员，此前曾担任Danish Crown A/S董事会成员，并曾任世界糖尿病基金会（World Diabetes Foundation）副主席。 “Eric...

WHEATON, Ill.--(BUSINESS WIRE)--First Trust Advisors L.P. (“FTA”) announces the First Trust RiverFront Dynamic Developed International ETF (Nasdaq: RFDI) (the “Fund”), a series of First Trust Exchange-Traded Fund III (the “Trust”), will change its investment strategies, name and other related matters, expected to occur on or around September 14, 2026. The Fund’s new name will be the First Trust Active Factor International ETF and the Fund’s new ticker will be AFDM. In connection with the change...

VICTOR, N.Y.--(BUSINESS WIRE)--Broadstone Net Lease Schedules Second Quarter 2026 Earnings Release and Conference Call...

WHEATON, Ill.--(BUSINESS WIRE)--First Trust Advisors L.P. (“FTA”) announces the First Trust RiverFront Dynamic Emerging Markets ETF (Nasdaq Inc.: RFEM) (the “Fund”), a series of First Trust Exchange-Traded Fund III (the “Trust”), will change its investment strategies, name and other related matters, expected to occur on or around September 14, 2026. The Fund’s new name will be the First Trust Active Factor Emerging Markets ETF and the Fund’s new ticker will be AFEM. In connection with the change...

BELLINGHAM, Wash.--(BUSINESS WIRE)--SPIE, la società internazionale di ottica e fotonica, invita la comunità di ottica e fotonica a candidarsi ai SPIE Prism Awards di quest'anno, che premiano nuovi prodotti straordinari che rivoluzionano il mercato. I vincitori verranno annunciati all'attesissima cerimonia di premiazione del 3 febbraio 2027 al SPIE Photonics West di San Francisco, California. Questi premi, noti come gli “Oscars della fotonica”, offrono a scienziati e ingegneri del settore dell'...

FREMONT, Calif.--(BUSINESS WIRE)--AXT, Inc. (NasdaqGS: AXTI), a leading manufacturer of compound semiconductor substrates, will announce its financial results for the second quarter 2026 in a press release immediately following the close of market on July 30, 2026. The company will also host a conference call to discuss these results on July 30, 2026 at 1:30 p.m. PT. The conference call can be accessed at (833) 461-5787 (passcode 630205921). The call will also be simulcast at www.axt.com. The w...